ArticleInternational journal of nanomedicine2025
In situ Antibiotic-Loaded Copper Tannic Acid Coordination Nanospheres Targeting Biofilms for the Treatment of Chronic Osteomyelitis.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The formation of biofilms hinders direct contact between antibiotics and bacteria, reducing the efficacy of antibiotic therapy and presenting a substantial obstacle to the treatment of chronic osteomyelitis. To address this problem, we successfully constructed a chemically and structurally robust vancomycin-copper-tannic acid (Van@CuTA) antibiotic sustained-release system via a simple synthetic method, to target bacteria and inhibit biofilm formation. Methods: Tannic acid (TA), copper ions (Cu Results: The developed nanospheres exhibited drug release properties, with TA being released from the carrier and inhibiting the formation of bacterial biofilms. In vivo experiments demonstrated inhibition of MRSA biofilm formation through the encapsulation of TA within fibrin and its sustained release, followed by the sequential release of Van and Cu Conclusion: This study offers a novel and promising strategy for the development of antimicrobial agents to combat MRSA-induced chronic osteomyelitis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.